GlassScriptPhysician profile
Amit Badiye
NPI 1245481944
$24,408.80
in general payments reported to CMS, 2019-2025
23 companies · $3,709 in 2025
The $3,709 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $1,861 · 2021: $935 · 2022: $7,115 · 2023: $2,160 · 2024: $6,750 · 2025: $3,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,598 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,315 · Travel and Lodging: $2,505 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,315.00 |
| Travel and Lodging | $2,504.77 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,259.41 | 2019-2025 | Optis, Triclip, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $5,988.24 | 2022-2025 | Camzyos |
| Abiomed | $2,335.23 | 2019-2025 | Impella |
| Boston Scientific Corporation | $1,168.27 | 2020-2025 | Watchman Flx |
| Ancora Heart, INC. | $989.71 | 2023 | Accucinch |
| Medtronic Vascular, INC. | $718.93 | 2019 | |
| Medtronic, INC. | $520.22 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Akcea Therapeutics, INC. | $319.04 | 2019-2020 | |
| Shockwave Medical, INC | $300.03 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $287.12 | 2019-2023 | |
| Cvrx, INC. | $286.86 | 2019-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $199.43 | 2019-2024 | Wainua |
| Philips North America LLC | $159.43 | 2023-2024 | (Bq9) Coronary Ivus |
| Endotronix, INC. | $145.58 | 2022 | |
| Livanova USA, INC. | $144.18 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $132.80 | 2019 | |
| Cardiovascular Systems INC. | $119.88 | 2021-2023 | Diamondback Coronary |
| Bayer Healthcare Pharmaceuticals INC. | $112.50 | 2024 | |
| Biosense Webster, INC. | $110.42 | 2025 | Carto 3 |
| Kiniksa Pharmaceuticals International, Plc | $65.33 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $28.91 | 2024 | |
| Inari Medical, INC. | $17.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Badiye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.